Medtronic Evolut™ TAVR platform outperforms surgery with sustained valve performance for low-risk patients at four years

/PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced four-year results from the Evolut Low Risk Trial. The...

Related Keywords

Ireland ,Dublin ,Prnewswire Medtronic ,Michael Reardon ,Rachel Murray ,Medtronic Evolut ,Ryan Weispfenning ,Linkedin ,Exchange Commission ,Cardiovascular Research Foundation ,Our Mission ,Medtronic ,Cardiovascular Research ,Journal Of The American College Cardiology ,Evolut Low Risk ,Only Evolut ,Transcatheter Cardiovascular Therapeutics ,American College ,Allison Family Distinguished Chair ,Houston Methodist Hospital ,Low Risk Trial ,Medtronic Plc ,